Clinical Trials Browser

Uveal Melanoma × pembrolizumab × Clear all

Uveal Melanoma

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 2 FDA

Dermatologic

Uveal Melanoma, Melanoma

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

420 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Phase 1/2 Recruiting

200 enrolled

DermatologicGastrointestinalThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT05282901 2025-11-24

PLUME

Phase 2 Active not recruiting

51 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Phase 1/2 Active not recruiting

35 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03611868 2025-08-07

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Phase 1/2 Active not recruiting

230 enrolled

DermatologicSarcoma

Uveal Melanoma, Melanoma, Neurofibrosarcoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Active not recruiting

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Phase 2 Active not recruiting

6 enrolled 11 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT04993677 2025-05-11

A Study of SEA-CD40 Given With Other Drugs in Cancers

Phase 2 Completed

77 enrolled 18 charts

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05576077 2025-03-10

STARLING

Phase 1 Terminated

31 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT02697630 2023-12-08

PEMDAC

Phase 2 Completed

29 enrolled

Dermatologic

Uveal Melanoma

NCT02359851 2019-09-18

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Phase 2 Terminated

5 enrolled 13 charts

Dermatologic

Uveal Melanoma

Clinical Trials

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

PLUME

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

A Study of SEA-CD40 Given With Other Drugs in Cancers

STARLING

PEMDAC

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma